L27.2
|
Dermatitis due to ingested food
|
T36.0X5A
|
Adverse effect of penicillins, initial encounter
|
T36.0X5D
|
Adverse effect of penicillins, subsequent encounter
|
T36.0X5S
|
Adverse effect of penicillins, sequela
|
T36.1X5A
|
Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter
|
T36.1X5D
|
Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter
|
T36.1X5S
|
Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela
|
T36.2X5A
|
Adverse effect of chloramphenicol group, initial encounter
|
T36.2X5D
|
Adverse effect of chloramphenicol group, subsequent encounter
|
T36.2X5S
|
Adverse effect of chloramphenicol group, sequela
|
T36.3X5A
|
Adverse effect of macrolides, initial encounter
|
T36.3X5D
|
Adverse effect of macrolides, subsequent encounter
|
T36.3X5S
|
Adverse effect of macrolides, sequela
|
T36.4X5A
|
Adverse effect of tetracyclines, initial encounter
|
T36.4X5D
|
Adverse effect of tetracyclines, subsequent encounter
|
T36.4X5S
|
Adverse effect of tetracyclines, sequela
|
T36.5X5A
|
Adverse effect of aminoglycosides, initial encounter
|
T36.5X5D
|
Adverse effect of aminoglycosides, subsequent encounter
|
T36.5X5S
|
Adverse effect of aminoglycosides, sequela
|
T36.6X5A
|
Adverse effect of rifampicins, initial encounter
|
T36.6X5D
|
Adverse effect of rifampicins, subsequent encounter
|
T36.6X5S
|
Adverse effect of rifampicins, sequela
|
T36.7X5A
|
Adverse effect of antifungal antibiotics, systemically used, initial encounter
|
T36.7X5D
|
Adverse effect of antifungal antibiotics, systemically used, subsequent encounter
|
T36.7X5S
|
Adverse effect of antifungal antibiotics, systemically used, sequela
|
T36.8X5A
|
Adverse effect of other systemic antibiotics, initial encounter
|
T36.8X5D
|
Adverse effect of other systemic antibiotics, subsequent encounter
|
T36.8X5S
|
Adverse effect of other systemic antibiotics, sequela
|
T37.0X5A
|
Adverse effect of sulfonamides, initial encounter
|
T37.0X5D
|
Adverse effect of sulfonamides, subsequent encounter
|
T37.0X5S
|
Adverse effect of sulfonamides, sequela
|
T37.1X5A
|
Adverse effect of antimycobacterial drugs, initial encounter
|
T37.1X5D
|
Adverse effect of antimycobacterial drugs, subsequent encounter
|
T37.1X5S
|
Adverse effect of antimycobacterial drugs, sequela
|
T37.2X5A
|
Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter
|
T37.2X5D
|
Adverse effect of antimalarials and drugs acting on other blood protozoa, subsequent encounter
|
T37.2X5S
|
Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela
|
T37.3X5A
|
Adverse effect of other antiprotozoal drugs, initial encounter
|
T37.3X5D
|
Adverse effect of other antiprotozoal drugs, subsequent encounter
|
T37.3X5S
|
Adverse effect of other antiprotozoal drugs, sequela
|
T37.4X5A
|
Adverse effect of anthelminthics, initial encounter
|
T37.4X5D
|
Adverse effect of anthelminthics, subsequent encounter
|
T37.4X5S
|
Adverse effect of anthelminthics, sequela
|
T37.5X5A
|
Adverse effect of antiviral drugs, initial encounter
|
T37.5X5D
|
Adverse effect of antiviral drugs, subsequent encounter
|
T37.5X5S
|
Adverse effect of antiviral drugs, sequela
|
T37.8X5A
|
Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter
|
T37.8X5D
|
Adverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter
|
T37.8X5S
|
Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela
|
T38.0X5A
|
Adverse effect of glucocorticoids and synthetic analogues, initial encounter
|
T38.0X5D
|
Adverse effect of glucocorticoids and synthetic analogues, subsequent encounter
|
T38.0X5S
|
Adverse effect of glucocorticoids and synthetic analogues, sequela
|
T38.1X5A
|
Adverse effect of thyroid hormones and substitutes, initial encounter
|
T38.1X5D
|
Adverse effect of thyroid hormones and substitutes, subsequent encounter
|
T38.1X5S
|
Adverse effect of thyroid hormones and substitutes, sequela
|
T38.2X5A
|
Adverse effect of antithyroid drugs, initial encounter
|
T38.2X5D
|
Adverse effect of antithyroid drugs, subsequent encounter
|
T38.2X5S
|
Adverse effect of antithyroid drugs, sequela
|
T38.3X5A
|
Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
|
T38.3X5D
|
Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, subsequent encounter
|
T38.3X5S
|
Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, sequela
|
T38.4X5A
|
Adverse effect of oral contraceptives, initial encounter
|
T38.4X5D
|
Adverse effect of oral contraceptives, subsequent encounter
|
T38.4X5S
|
Adverse effect of oral contraceptives, sequela
|
T38.5X5A
|
Adverse effect of other estrogens and progestogens, initial encounter
|
T38.5X5D
|
Adverse effect of other estrogens and progestogens, subsequent encounter
|
T38.5X5S
|
Adverse effect of other estrogens and progestogens, sequela
|
T38.6X5A
|
Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter
|
T38.6X5D
|
Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, subsequent encounter
|
T38.6X5S
|
Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela
|
T38.7X5A
|
Adverse effect of androgens and anabolic congeners, initial encounter
|
T38.7X5D
|
Adverse effect of androgens and anabolic congeners, subsequent encounter
|
T38.7X5S
|
Adverse effect of androgens and anabolic congeners, sequela
|
T38.815A
|
Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter
|
T38.815D
|
Adverse effect of anterior pituitary [adenohypophyseal] hormones, subsequent encounter
|
T38.815S
|
Adverse effect of anterior pituitary [adenohypophyseal] hormones, sequela
|
T38.895A
|
Adverse effect of other hormones and synthetic substitutes, initial encounter
|
T38.895D
|
Adverse effect of other hormones and synthetic substitutes, subsequent encounter
|
T38.895S
|
Adverse effect of other hormones and synthetic substitutes, sequela
|
T38.995A
|
Adverse effect of other hormone antagonists, initial encounter
|
T38.995D
|
Adverse effect of other hormone antagonists, subsequent encounter
|
T38.995S
|
Adverse effect of other hormone antagonists, sequela
|
T39.015A
|
Adverse effect of aspirin, initial encounter
|
T39.015D
|
Adverse effect of aspirin, subsequent encounter
|
T39.015S
|
Adverse effect of aspirin, sequela
|
T39.095A
|
Adverse effect of salicylates, initial encounter
|
T39.095D
|
Adverse effect of salicylates, subsequent encounter
|
T39.095S
|
Adverse effect of salicylates, sequela
|
T39.1X5A
|
Adverse effect of 4-Aminophenol derivatives, initial encounter
|
T39.1X5D
|
Adverse effect of 4-Aminophenol derivatives, subsequent encounter
|
T39.1X5S
|
Adverse effect of 4-Aminophenol derivatives, sequela
|
T39.2X5A
|
Adverse effect of pyrazolone derivatives, initial encounter
|
T39.2X5D
|
Adverse effect of pyrazolone derivatives, subsequent encounter
|
T39.2X5S
|
Adverse effect of pyrazolone derivatives, sequela
|
T39.315A
|
Adverse effect of propionic acid derivatives, initial encounter
|
T39.315D
|
Adverse effect of propionic acid derivatives, subsequent encounter
|
T39.315S
|
Adverse effect of propionic acid derivatives, sequela
|
T39.395A
|
Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
|
T39.395D
|
Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter
|
T39.395S
|
Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
|
T39.4X5A
|
Adverse effect of antirheumatics, not elsewhere classified, initial encounter
|
T39.4X5D
|
Adverse effect of antirheumatics, not elsewhere classified, subsequent encounter
|
T39.4X5S
|
Adverse effect of antirheumatics, not elsewhere classified, sequela
|
T39.8X5A
|
Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter
|
T39.8X5D
|
Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter
|
T39.8X5S
|
Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
|
T44.3X5A
|
Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
|
T44.3X5D
|
Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
|
T44.3X5S
|
Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
|
T44.4X5A
|
Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
|
T44.4X5D
|
Adverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter
|
T44.4X5S
|
Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela
|
T44.5X5A
|
Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
|
T44.5X5D
|
Adverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter
|
T44.5X5S
|
Adverse effect of predominantly beta-adrenoreceptor agonists, sequela
|
T44.6X5A
|
Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
|
T44.6X5D
|
Adverse effect of alpha-adrenoreceptor antagonists, subsequent encounter
|
T44.6X5S
|
Adverse effect of alpha-adrenoreceptor antagonists, sequela
|
T44.7X5A
|
Adverse effect of beta-adrenoreceptor antagonists, initial encounter
|
T44.7X5D
|
Adverse effect of beta-adrenoreceptor antagonists, subsequent encounter
|
T44.7X5S
|
Adverse effect of beta-adrenoreceptor antagonists, sequela
|
T44.8X5A
|
Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
|
T44.8X5D
|
Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
|
T44.8X5S
|
Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
|
T44.995A
|
Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
|
T44.995D
|
Adverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter
|
T44.995S
|
Adverse effect of other drug primarily affecting the autonomic nervous system, sequela
|
T45.0X5A
|
Adverse effect of antiallergic and antiemetic drugs, initial encounter
|
T45.0X5D
|
Adverse effect of antiallergic and antiemetic drugs, subsequent encounter
|
T45.0X5S
|
Adverse effect of antiallergic and antiemetic drugs, sequela
|
T45.1X5A
|
Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
|
T45.1X5D
|
Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
|
T45.1X5S
|
Adverse effect of antineoplastic and immunosuppressive drugs, sequela
|
T45.2X5A
|
Adverse effect of vitamins, initial encounter
|
T45.2X5D
|
Adverse effect of vitamins, subsequent encounter
|
T45.2X5S
|
Adverse effect of vitamins, sequela
|
T45.3X5A
|
Adverse effect of enzymes, initial encounter
|
T45.3X5D
|
Adverse effect of enzymes, subsequent encounter
|
T45.3X5S
|
Adverse effect of enzymes, sequela
|
T45.4X5A
|
Adverse effect of iron and its compounds, initial encounter
|
T45.4X5D
|
Adverse effect of iron and its compounds, subsequent encounter
|
T45.4X5S
|
Adverse effect of iron and its compounds, sequela
|
T45.515A
|
Adverse effect of anticoagulants, initial encounter
|
T45.515D
|
Adverse effect of anticoagulants, subsequent encounter
|
T45.515S
|
Adverse effect of anticoagulants, sequela
|
T45.525A
|
Adverse effect of antithrombotic drugs, initial encounter
|
T45.525D
|
Adverse effect of antithrombotic drugs, subsequent encounter
|
T45.525S
|
Adverse effect of antithrombotic drugs, sequela
|
T45.615A
|
Adverse effect of thrombolytic drugs, initial encounter
|
T45.615D
|
Adverse effect of thrombolytic drugs, subsequent encounter
|
T45.615S
|
Adverse effect of thrombolytic drugs, sequela
|
T45.625A
|
Adverse effect of hemostatic drug, initial encounter
|
T45.625D
|
Adverse effect of hemostatic drug, subsequent encounter
|
T45.625S
|
Adverse effect of hemostatic drug, sequela
|
T45.695A
|
Adverse effect of other fibrinolysis-affecting drugs, initial encounter
|
T45.695D
|
Adverse effect of other fibrinolysis-affecting drugs, subsequent encounter
|
T45.695S
|
Adverse effect of other fibrinolysis-affecting drugs, sequela
|
T45.7X5A
|
Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter
|
T45.7X5D
|
Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, subsequent encounter
|
T45.7X5S
|
Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela
|
T45.8X5A
|
Adverse effect of other primarily systemic and hematological agents, initial encounter
|
T45.8X5D
|
Adverse effect of other primarily systemic and hematological agents, subsequent encounter
|
T45.8X5S
|
Adverse effect of other primarily systemic and hematological agents, sequela
|
T46.0X5A
|
Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
|
T46.0X5D
|
Adverse effect of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter
|
T46.0X5S
|
Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela
|
T46.1X5A
|
Adverse effect of calcium-channel blockers, initial encounter
|
T46.1X5D
|
Adverse effect of calcium-channel blockers, subsequent encounter
|
T46.1X5S
|
Adverse effect of calcium-channel blockers, sequela
|
T46.2X5A
|
Adverse effect of other antidysrhythmic drugs, initial encounter
|
T46.2X5D
|
Adverse effect of other antidysrhythmic drugs, subsequent encounter
|
T46.2X5S
|
Adverse effect of other antidysrhythmic drugs, sequela
|
T46.3X5A
|
Adverse effect of coronary vasodilators, initial encounter
|
T46.3X5D
|
Adverse effect of coronary vasodilators, subsequent encounter
|
T46.3X5S
|
Adverse effect of coronary vasodilators, sequela
|
T46.4X5A
|
Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
|
T46.4X5D
|
Adverse effect of angiotensin-converting-enzyme inhibitors, subsequent encounter
|
T46.4X5S
|
Adverse effect of angiotensin-converting-enzyme inhibitors, sequela
|
T46.5X5A
|
Adverse effect of other antihypertensive drugs, initial encounter
|
T46.5X5D
|
Adverse effect of other antihypertensive drugs, subsequent encounter
|
T46.5X5S
|
Adverse effect of other antihypertensive drugs, sequela
|
T46.6X5A
|
Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
|
T46.6X5D
|
Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter
|
T46.6X5S
|
Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
|
T46.7X5A
|
Adverse effect of peripheral vasodilators, initial encounter
|
T46.7X5D
|
Adverse effect of peripheral vasodilators, subsequent encounter
|
T46.7X5S
|
Adverse effect of peripheral vasodilators, sequela
|
T46.8X5A
|
Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
|
T46.8X5D
|
Adverse effect of antivaricose drugs, including sclerosing agents, subsequent encounter
|
T46.8X5S
|
Adverse effect of antivaricose drugs, including sclerosing agents, sequela
|
T46.995A
|
Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
|
T46.995D
|
Adverse effect of other agents primarily affecting the cardiovascular system, subsequent encounter
|
T46.995S
|
Adverse effect of other agents primarily affecting the cardiovascular system, sequela
|
T47.0X5A
|
Adverse effect of histamine H2-receptor blockers, initial encounter
|
T47.0X5D
|
Adverse effect of histamine H2-receptor blockers, subsequent encounter
|
T47.0X5S
|
Adverse effect of histamine H2-receptor blockers, sequela
|
T47.1X5A
|
Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
|
T47.1X5D
|
Adverse effect of other antacids and anti-gastric-secretion drugs, subsequent encounter
|
T47.1X5S
|
Adverse effect of other antacids and anti-gastric-secretion drugs, sequela
|
T47.2X5A
|
Adverse effect of stimulant laxatives, initial encounter
|
T47.2X5D
|
Adverse effect of stimulant laxatives, subsequent encounter
|
T47.2X5S
|
Adverse effect of stimulant laxatives, sequela
|
T47.3X5A
|
Adverse effect of saline and osmotic laxatives, initial encounter
|
T47.3X5D
|
Adverse effect of saline and osmotic laxatives, subsequent encounter
|
T47.3X5S
|
Adverse effect of saline and osmotic laxatives, sequela
|
T47.4X5A
|
Adverse effect of other laxatives, initial encounter
|
T47.4X5D
|
Adverse effect of other laxatives, subsequent encounter
|
T47.4X5S
|
Adverse effect of other laxatives, sequela
|
T47.5X5A
|
Adverse effect of digestants, initial encounter
|
T47.5X5D
|
Adverse effect of digestants, subsequent encounter
|
T47.5X5S
|
Adverse effect of digestants, sequela
|
T47.6X5A
|
Adverse effect of antidiarrheal drugs, initial encounter
|
T47.6X5D
|
Adverse effect of antidiarrheal drugs, subsequent encounter
|
T47.6X5S
|
Adverse effect of antidiarrheal drugs, sequela
|
T47.7X5A
|
Adverse effect of emetics, initial encounter
|
T47.7X5D
|
Adverse effect of emetics, subsequent encounter
|
T47.7X5S
|
Adverse effect of emetics, sequela
|
T47.8X5A
|
Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
|
T47.8X5D
|
Adverse effect of other agents primarily affecting gastrointestinal system, subsequent encounter
|
T47.8X5S
|
Adverse effect of other agents primarily affecting gastrointestinal system, sequela
|
T48.0X5A
|
Adverse effect of oxytocic drugs, initial encounter
|
T48.0X5D
|
Adverse effect of oxytocic drugs, subsequent encounter
|
T48.0X5S
|
Adverse effect of oxytocic drugs, sequela
|
T48.1X5A
|
Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
|
T48.1X5D
|
Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter
|
T48.1X5S
|
Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela
|
T48.295A
|
Adverse effect of other drugs acting on muscles, initial encounter
|
T48.295D
|
Adverse effect of other drugs acting on muscles, subsequent encounter
|
T48.295S
|
Adverse effect of other drugs acting on muscles, sequela
|
T48.3X5A
|
Adverse effect of antitussives, initial encounter
|
T48.3X5D
|
Adverse effect of antitussives, subsequent encounter
|
T48.3X5S
|
Adverse effect of antitussives, sequela
|
T48.4X5A
|
Adverse effect of expectorants, initial encounter
|
T48.4X5D
|
Adverse effect of expectorants, subsequent encounter
|
T48.4X5S
|
Adverse effect of expectorants, sequela
|
T48.5X5A
|
Adverse effect of other anti-common-cold drugs, initial encounter
|
T48.5X5D
|
Adverse effect of other anti-common-cold drugs, subsequent encounter
|
T48.5X5S
|
Adverse effect of other anti-common-cold drugs, sequela
|
T48.6X5A
|
Adverse effect of antiasthmatics, initial encounter
|
T48.6X5D
|
Adverse effect of antiasthmatics, subsequent encounter
|
T48.6X5S
|
Adverse effect of antiasthmatics, sequela
|
T48.995A
|
Adverse effect of other agents primarily acting on the respiratory system, initial encounter
|
T48.995D
|
Adverse effect of other agents primarily acting on the respiratory system, subsequent encounter
|
T48.995S
|
Adverse effect of other agents primarily acting on the respiratory system, sequela
|
T49.5X5A
|
Adverse effect of ophthalmological drugs and preparations, initial encounter
|
T49.5X5D
|
Adverse effect of ophthalmological drugs and preparations, subsequent encounter
|
T49.5X5S
|
Adverse effect of ophthalmological drugs and preparations, sequela
|
T50.0X5A
|
Adverse effect of mineralocorticoids and their antagonists, initial encounter
|
T50.0X5D
|
Adverse effect of mineralocorticoids and their antagonists, subsequent encounter
|
T50.0X5S
|
Adverse effect of mineralocorticoids and their antagonists, sequela
|
T50.1X5A
|
Adverse effect of loop [high-ceiling] diuretics, initial encounter
|
T50.1X5D
|
Adverse effect of loop [high-ceiling] diuretics, subsequent encounter
|
T50.1X5S
|
Adverse effect of loop [high-ceiling] diuretics, sequela
|
T50.2X5A
|
Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter
|
T50.2X5D
|
Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, subsequent encounter
|
T50.2X5S
|
Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela
|
T50.3X5A
|
Adverse effect of electrolytic, caloric and water-balance agents, initial encounter
|
T50.3X5D
|
Adverse effect of electrolytic, caloric and water-balance agents, subsequent encounter
|
T50.3X5S
|
Adverse effect of electrolytic, caloric and water-balance agents, sequela
|
T50.4X5A
|
Adverse effect of drugs affecting uric acid metabolism, initial encounter
|
T50.4X5D
|
Adverse effect of drugs affecting uric acid metabolism, subsequent encounter
|
T50.4X5S
|
Adverse effect of drugs affecting uric acid metabolism, sequela
|
T50.5X5A
|
Adverse effect of appetite depressants, initial encounter
|
T50.5X5D
|
Adverse effect of appetite depressants, subsequent encounter
|
T50.5X5S
|
Adverse effect of appetite depressants, sequela
|
T50.7X5A
|
Adverse effect of analeptics and opioid receptor antagonists, initial encounter
|
T50.7X5D
|
Adverse effect of analeptics and opioid receptor antagonists, subsequent encounter
|
T50.7X5S
|
Adverse effect of analeptics and opioid receptor antagonists, sequela
|
T50.8X5A
|
Adverse effect of diagnostic agents, initial encounter
|
T50.8X5D
|
Adverse effect of diagnostic agents, subsequent encounter
|
T50.8X5S
|
Adverse effect of diagnostic agents, sequela
|
T50.A15A
|
Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter
|
T50.A15D
|
Adverse effect of pertussis vaccine, including combinations with a pertussis component, subsequent encounter
|
T50.A15S
|
Adverse effect of pertussis vaccine, including combinations with a pertussis component, sequela
|
T50.A25A
|
Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter
|
T50.A25D
|
Adverse effect of mixed bacterial vaccines without a pertussis component, subsequent encounter
|
T50.A25S
|
Adverse effect of mixed bacterial vaccines without a pertussis component, sequela
|
T50.A95A
|
Adverse effect of other bacterial vaccines, initial encounter
|
T50.A95D
|
Adverse effect of other bacterial vaccines, subsequent encounter
|
T50.A95S
|
Adverse effect of other bacterial vaccines, sequela
|
T50.B95A
|
Adverse effect of other viral vaccines, initial encounter
|
T50.B95D
|
Adverse effect of other viral vaccines, subsequent encounter
|
T50.B95S
|
Adverse effect of other viral vaccines, sequela
|
T50.Z15A
|
Adverse effect of immunoglobulin, initial encounter
|
T50.Z15D
|
Adverse effect of immunoglobulin, subsequent encounter
|
T50.Z15S
|
Adverse effect of immunoglobulin, sequela
|
T50.Z95A
|
Adverse effect of other vaccines and biological substances, initial encounter
|
T50.Z95D
|
Adverse effect of other vaccines and biological substances, subsequent encounter
|
T50.Z95S
|
Adverse effect of other vaccines and biological substances, sequela
|
T50.995A
|
Adverse effect of other drugs, medicaments and biological substances, initial encounter
|
T50.995D
|
Adverse effect of other drugs, medicaments and biological substances, subsequent encounter
|
T50.995S
|
Adverse effect of other drugs, medicaments and biological substances, sequela
|
T78.01XA
|
Anaphylactic reaction due to peanuts, initial encounter
|
T78.01XD
|
Anaphylactic reaction due to peanuts, subsequent encounter
|
T78.01XS
|
Anaphylactic reaction due to peanuts, sequela
|
T78.02XA
|
Anaphylactic reaction due to shellfish (crustaceans), initial encounter
|
T78.02XD
|
Anaphylactic reaction due to shellfish (crustaceans), subsequent encounter
|
T78.02XS
|
Anaphylactic reaction due to shellfish (crustaceans), sequela
|
T78.03XA
|
Anaphylactic reaction due to other fish, initial encounter
|
T78.03XD
|
Anaphylactic reaction due to other fish, subsequent encounter
|
T78.03XS
|
Anaphylactic reaction due to other fish, sequela
|
T78.04XA
|
Anaphylactic reaction due to fruits and vegetables, initial encounter
|
T78.04XD
|
Anaphylactic reaction due to fruits and vegetables, subsequent encounter
|
T78.04XS
|
Anaphylactic reaction due to fruits and vegetables, sequela
|
T78.05XA
|
Anaphylactic reaction due to tree nuts and seeds, initial encounter
|
T78.05XD
|
Anaphylactic reaction due to tree nuts and seeds, subsequent encounter
|
T78.05XS
|
Anaphylactic reaction due to tree nuts and seeds, sequela
|
T78.06XA
|
Anaphylactic reaction due to food additives, initial encounter
|
T78.06XD
|
Anaphylactic reaction due to food additives, subsequent encounter
|
T78.06XS
|
Anaphylactic reaction due to food additives, sequela
|
T78.07XA
|
Anaphylactic reaction due to milk and dairy products, initial encounter
|
T78.07XD
|
Anaphylactic reaction due to milk and dairy products, subsequent encounter
|
T78.07XS
|
Anaphylactic reaction due to milk and dairy products, sequela
|
T78.08XA
|
Anaphylactic reaction due to eggs, initial encounter
|
T78.08XD
|
Anaphylactic reaction due to eggs, subsequent encounter
|
T78.08XS
|
Anaphylactic reaction due to eggs, sequela
|
T78.09XA
|
Anaphylactic reaction due to other food products, initial encounter
|
T78.09XD
|
Anaphylactic reaction due to other food products, subsequent encounter
|
T78.09XS
|
Anaphylactic reaction due to other food products, sequela
|
T78.1XXA
|
Other adverse food reactions, not elsewhere classified, initial encounter
|
T78.1XXD
|
Other adverse food reactions, not elsewhere classified, subsequent encounter
|
T78.1XXS
|
Other adverse food reactions, not elsewhere classified, sequela
|
Z88.0
|
Allergy status to penicillin
|
Z88.1
|
Allergy status to other antibiotic agents
|
Z88.2
|
Allergy status to sulfonamides
|
Z88.3
|
Allergy status to other anti-infective agents
|
Z88.4
|
Allergy status to anesthetic agent
|
Z88.5
|
Allergy status to narcotic agent
|
Z88.6
|
Allergy status to analgesic agent
|
Z88.7
|
Allergy status to serum and vaccine
|
Z88.8
|
Allergy status to other drugs, medicaments and biological substances
|
Z91.010
|
Allergy to peanuts
|
Z91.011
|
Allergy to milk products
|
Z91.012
|
Allergy to eggs
|
Z91.013
|
Allergy to seafood
|
Z91.014
|
Allergy to mammalian meats
|
Z91.018
|
Allergy to other foods
|